TY - JOUR
T1 - Therapeutic Perspectives of HIV-Associated Chemokine Receptor (CCR5 and CXCR4) Antagonists in Carcinomas
AU - González-Arriagada, Wilfredo Alejandro
AU - García, Isaac E.
AU - Martínez-Flores, René
AU - Morales-Pison, Sebastián
AU - Coletta, Ricardo D.
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/12/28
Y1 - 2022/12/28
N2 - The interaction between malignant cells and the tumor microenvironment is critical for tumor progression, and the chemokine ligand/receptor axes play a crucial role in this process. The CXCR4/CXCL12 and CCR5/CCL5 axes, both related to HIV, have been associated with the early (epithelial–mesenchymal transition and invasion) and late events (migration and metastasis) of cancer progression. In addition, these axes can also modulate the immune response against tumors. Thus, antagonists against the receptors of these axes have been proposed in cancer therapy. Although preclinical studies have shown promising results, clinical trials are needed to include these drugs in the oncological treatment protocols. New alternatives for these antagonists, such as dual CXCR4/CCR5 antagonists or combined therapy in association with immunotherapy, need to be studied in cancer therapy.
AB - The interaction between malignant cells and the tumor microenvironment is critical for tumor progression, and the chemokine ligand/receptor axes play a crucial role in this process. The CXCR4/CXCL12 and CCR5/CCL5 axes, both related to HIV, have been associated with the early (epithelial–mesenchymal transition and invasion) and late events (migration and metastasis) of cancer progression. In addition, these axes can also modulate the immune response against tumors. Thus, antagonists against the receptors of these axes have been proposed in cancer therapy. Although preclinical studies have shown promising results, clinical trials are needed to include these drugs in the oncological treatment protocols. New alternatives for these antagonists, such as dual CXCR4/CCR5 antagonists or combined therapy in association with immunotherapy, need to be studied in cancer therapy.
KW - CCR5 Receptor Antagonists/therapeutic use
KW - Carcinoma/drug therapy
KW - Chemokine CXCL12
KW - Humans
KW - Receptors, CCR5
KW - Receptors, CXCR4/antagonists & inhibitors
KW - Signal Transduction
KW - Tumor Microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85145952073&partnerID=8YFLogxK
U2 - 10.3390/ijms24010478
DO - 10.3390/ijms24010478
M3 - Review article
C2 - 36613922
AN - SCOPUS:85145952073
SN - 1661-6596
VL - 24
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 1
M1 - 478
ER -
